Gert Weijers

Gert Weijers

Auto-generated profile, based on publicly available information

Gert Weijers

Medical Ultrasound Imaging Centre, Department of Medical Imaging, Radboud University Medical Centre, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
JTJohan M. Thijssen
Johan M. Thijssen
GWGert Weijers
Gert Weijers
CKChris L. de Korte
Chris L. de Korte

19 March 2009 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
SPSigrid Pillen
Sigrid Pillen
Johannes Van DijkJohannes Van Dijk
Johannes Van Dijk
GWGert Weijers
Gert Weijers
WRWilma Raijmann
Wilma Raijmann
CKChris L. de Korte
Chris L. de Korte
MZMachiel J. Zwarts
Machiel J. Zwarts

3 June 2008 in IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control
Verified
Journal Article
Closed access
JTJohan M. Thijssen
Johan M. Thijssen
ASAlexander Starke
Alexander Starke
GWGert Weijers
Gert Weijers
AHAlois Haudum
Alois Haudum
KHKathrin Herzog
Kathrin Herzog
CKChris L. De Korte
Chris L. De Korte
Fatty liver (steatosis) occurs in obese patients, among others, and is related to the development of diabetes type-2. Timely diagnosis of steatosis is therefore of great importance. Steatosis is also the most common liver disease of high-yielding dairy cattle during early lactation. This makes it a suitable animal model for studying liver steatosis. Furthermore, reference of derived ultrasound parameters against a "gold standard" is possible in cattle by taking a liver biopsy for the assessment of fat concentration. The authors undertook this pilot study to investigate the hypothesis that quantitative, computer-aided B- mode ultrasound enables the noninvasive detection of hepatic steatosis. Echographic images were obtained postpartum from dairy cows (n = 12) in transcutaneous and direct (intraoperative) applications using a convex array transducer at 4.2 MHz. During surgery, a biopsy was taken from the caudate lobe to assess the liver fat content (fat score). A custom-designed software package for computer-aided ultrasound diagnosis (CAUS) was developed. After linearizing the post-processing look-up-table (LUT), the image gray levels were transferred into echo levels in decibels relative to the mean echo level in a tissue-mimicking phantom. The quantitative comparison of transcutaneous and intraoperative images enabled the correction for the attenuation effect of skin and subcutaneous fat layer on the mean echo level in the liver, as well as for the effects of the beam formation and attenuation of liver tissue on the echo level vs. depth. The residual attenuation coefficient (dB/cm) in fatty liver vs. normal liver was estimated and compensated for. Finally, echo level was estimated relative to the phantom used for calibration, and echo texture was characterized by the mean axial and lateral speckle size within the regions of interest. In the no fat/low fat group (n = 5) skin plus fat layer attenuation was 3.4 dB/cm. A correlation of skin layer thickness vs. fat score of r = 0.48 was found. The mean transcutaneous liver tissue echo level correlated well with fat score: r = 0.80. A residual liver attenuation coefficient of 0.76 dB/cm and 1.19 dB/cm was found in medium and high fat liver, respectively. In transcutaneous images, correlation of residual attenuation coefficient with fat score was r = 0.69. Axial and lateral speckle sizes were on the order of 0.2 and 1.0 cm, respectively, and no correlation was found with liver fat content. Results for transcutaneous and intraoperative images were similar. The authors conclude that this pilot study shows the feasibility of calibrated, computer-aided ultrasound for noninvasively diagnosing, possibly even screening, steatosis of the liver.

13 May 2015
Verified
Book Chapter
Closed access
PDF file
SKSaskia Koene
Saskia Koene
PLPaul de Laat
Paul de Laat
DTDoorlène H. van Tienoven
Doorlène H. van Tienoven
GWGert Weijers
Gert Weijers
Dennis VriensDennis Vriens
Dennis Vriens
JSJan A. M. Smeitink
Jan A. M. Smeitink

20 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
WVWilhelm A.J.W. Vos
Wilhelm A.J.W. Vos
AGAlbert Groenendijk
Albert Groenendijk
MBMarc J. T. Blaauw
Marc J. T. Blaauw
LELouise E. van Eekeren
Louise E. van Eekeren
ANAdriana Navas
Adriana Navas
AVAndre J. A. M. van der Ven
Andre J. A. M. van der Ven
Background: Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets.Methods: The 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort.Results: Overall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%) cis-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine.Conclusion: The 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV.

1 April 2009 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
GWGert Weijers
Gert Weijers
JGJacqueline Groot-Loonen
Jacqueline Groot-Loonen
MPMilanthy Pourier
Milanthy Pourier
TFTon Feuth
Ton Feuth
LKLivia Kapusta
Livia Kapusta